Id: | acc3268 |
Group: | 2sens |
Protein: | GSK3beta |
Gene Symbol: | GSK3B |
Protein Id: | P49841 |
Protein Name: | GSK3B_HUMAN |
PTM: | phosphorylation |
Site: | Ser9 |
Site Sequence: | -MSGRPRTTSFAESCKPVQQP |
Disease Category: | Cancer |
Disease: | Neuroblastoma |
Disease Subtype: | |
Disease Cellline: | SH-SY5Y |
Disease Info: | |
Drug: | curcumin |
Drug Info: | "Curcumin is a natural polyphenol compound commonly found in turmeric, known for its anti - inflammatory and antioxidant properties." |
Effect: | modulate |
Effect Info: | Curcumin inhibits Aβ-induced excessive phosphorylation of tau. No disease impact is indicated. |
Note: | |
Score: | 2.0 |
Pubmed(PMID): | 24188406 |
Sentence Index: | 24188406_4-5 |
Sentence: | "In this study, cellular signaling of tau phosphorylation induced by Abeta and the inhibiting effects of curcumin on this signaling were investigated on human neuroblastoma SH-SY5Y cells. The results indicated that curcumin inhibits Abeta-induced tau phosphorylation at Thr231 and Ser396, over-expression of HDAC6, and decrease in phosphorylation of glycogen synthase kinase-3beta (GSK-3beta) at Ser9." |
Sequence & Structure:
MSGRPRTTSFAESCKPVQQPSAFGSMKVSRDKDGSKVTTVVATPGQGPDRPQEVSYTDTKVIGNGSFGVVYQAKLCDSGELVAIKKVLQDKRFKNRELQIMRKLDHCNIVRLRYFFYSSGEKKDEVYLNLVLDYVPETVYRVARHYSRAKQTLPVIYVKLYMYQLFRSLAYIHSFGICHRDIKPQNLLLDPDTAVLKLCDFGSAKQLVRGEPNVSYICSRYYRAPELIFGATDYTSSIDVWSAGCVLAELLLGQPIFPGDSGVDQLVEIIKVLGTPTREQIREMNPNYTEFKFPQIKAHPWTKVFRPRTPPEAIALCSRLLEYTPTARLTPLEACAHSFFDELRDPNVKLPNGRDTPALFNFTTQELSSNPPLATILIPPHARIQAAASTPTNATAASDANTGDRGQTNNAASASASNST
Select PDB:
Target | Drug name | MOA | Phase | Status | Disease | Source |
---|---|---|---|---|---|---|
GSK3B | LITHIUM CARBONATE | Glycogen synthase kinase-3 inhibitor | 4 | - | bipolar I disorder | DailyMed DailyMed DailyMed |
GSK3B | LITHIUM CARBONATE | Glycogen synthase kinase-3 inhibitor | 4 | Completed | bipolar I disorder | ClinicalTrials ClinicalTrials |
GSK3B | LITHIUM CARBONATE | Glycogen synthase kinase-3 inhibitor | 4 | Withdrawn | bipolar I disorder | ClinicalTrials |
GSK3B | LITHIUM CARBONATE | Glycogen synthase kinase-3 inhibitor | 4 | Unknown status | bipolar I disorder | ClinicalTrials ClinicalTrials |
GSK3B | LITHIUM CITRATE | Glycogen synthase kinase-3 inhibitor | 4 | - | bipolar I disorder | DailyMed |
GSK3B | LITHIUM CARBONATE | Glycogen synthase kinase-3 inhibitor | 4 | Completed | depressive disorder | ClinicalTrials ClinicalTrials ClinicalTrials ClinicalTrials ClinicalTrials ClinicalTrials ClinicalTrials |
GSK3B | LITHIUM CARBONATE | Glycogen synthase kinase-3 inhibitor | 4 | Terminated | depressive disorder | ClinicalTrials |
GSK3B | LITHIUM CARBONATE | Glycogen synthase kinase-3 inhibitor | 4 | Unknown status | depressive disorder | ClinicalTrials ClinicalTrials ClinicalTrials |
GSK3B | LITHIUM CARBONATE | Glycogen synthase kinase-3 inhibitor | 4 | - | major depressive disorder | DailyMed |
GSK3B | LITHIUM CARBONATE | Glycogen synthase kinase-3 inhibitor | 4 | Recruiting | depressive disorder | ClinicalTrials |
GSK3B | LITHIUM CARBONATE | Glycogen synthase kinase-3 inhibitor | 4 | Completed | bipolar disorder | ClinicalTrials ClinicalTrials ClinicalTrials ClinicalTrials ClinicalTrials ClinicalTrials ClinicalTrials ClinicalTrials ClinicalTrials ClinicalTrials ClinicalTrials ClinicalTrials ClinicalTrials ClinicalTrials ClinicalTrials ClinicalTrials ClinicalTrials ClinicalTrials ClinicalTrials ClinicalTrials ClinicalTrials ClinicalTrials ClinicalTrials |
GSK3B | LITHIUM CARBONATE | Glycogen synthase kinase-3 inhibitor | 4 | Unknown status | bipolar disorder | ClinicalTrials ClinicalTrials ClinicalTrials ClinicalTrials |
GSK3B | LITHIUM CARBONATE | Glycogen synthase kinase-3 inhibitor | 4 | - | bipolar disorder | DailyMed DailyMed DailyMed DailyMed DailyMed DailyMed DailyMed DailyMed DailyMed DailyMed DailyMed DailyMed DailyMed DailyMed DailyMed DailyMed DailyMed DailyMed DailyMed DailyMed DailyMed DailyMed DailyMed DailyMed DailyMed DailyMed DailyMed DailyMed DailyMed DailyMed DailyMed DailyMed DailyMed DailyMed DailyMed DailyMed DailyMed DailyMed DailyMed DailyMed DailyMed DailyMed DailyMed DailyMed DailyMed |
GSK3B | LITHIUM CARBONATE | Glycogen synthase kinase-3 inhibitor | 4 | Recruiting | bipolar disorder | ClinicalTrials ClinicalTrials |
GSK3B | LITHIUM CARBONATE | Glycogen synthase kinase-3 inhibitor | 4 | Terminated | bipolar disorder | ClinicalTrials ClinicalTrials ClinicalTrials ClinicalTrials |
GSK3B | LITHIUM CARBONATE | Glycogen synthase kinase-3 inhibitor | 4 | Withdrawn | bipolar disorder | ClinicalTrials ClinicalTrials |
GSK3B | LITHIUM CARBONATE | Glycogen synthase kinase-3 inhibitor | 3 | Completed | stroke | ClinicalTrials |
GSK3B | LITHIUM CARBONATE | Glycogen synthase kinase-3 inhibitor | 3 | Recruiting | internal carotid artery stenosis | ClinicalTrials |
GSK3B | LITHIUM CARBONATE | Glycogen synthase kinase-3 inhibitor | 3 | Completed | aggressive behavior | ClinicalTrials |
GSK3B | LITHIUM CARBONATE | Glycogen synthase kinase-3 inhibitor | 3 | Recruiting | carotid artery disease | ClinicalTrials |
GSK3B | LITHIUM CARBONATE | Glycogen synthase kinase-3 inhibitor | 3 | Active, not recruiting | autism spectrum disorder | ClinicalTrials |
GSK3B | LITHIUM CARBONATE | Glycogen synthase kinase-3 inhibitor | 3 | Completed | conduct disorder | ClinicalTrials |
GSK3B | LITHIUM CARBONATE | Glycogen synthase kinase-3 inhibitor | 3 | Terminated | anxiety | ClinicalTrials |
GSK3B | LITHIUM CARBONATE | Glycogen synthase kinase-3 inhibitor | 3 | Completed | treatment resistant depression | ClinicalTrials |
GSK3B | LITHIUM CARBONATE | Glycogen synthase kinase-3 inhibitor | 3 | Completed | bipolar I disorder | ClinicalTrials ClinicalTrials ClinicalTrials ClinicalTrials |
Note: Only show clinically investigational or approved drugs with protein targets.
Protein Tractability:
source: Open TargetsPTM Intensity:
source: CPTACGSK3B-Ser9 | |
---|---|
Cancer | Intensity |
BRCA | |
COAD | -0.707 |
HGSC | 0.707 |
ccRCC | |
GBM | |
HNSC | |
LUAD | |
LUSC | |
non_ccRCC | |
PDAC | |
UCEC |
PTM-Disease Association:
source: PTMDResidue | Position | State | Disease | Class | PMID |
---|---|---|---|---|---|
S | 9 | D | Diabetes mellitus | Phosphorylation | 15033922 |
S | 9 | D | Pancreatic cancer/carcinoma/adenocarcinoma | Phosphorylation | 23408967 |
S | 9 | D | Triple-negative breast cancer | Phosphorylation | 35090098 |
S | 9 | D | Alzheimer's disease | Phosphorylation | 22278060 |
S | 9 | D | Schizophrenia | Phosphorylation | 14745448 |
S | 9 | D | Parkinson's disease | Phosphorylation | 27609071 |
S | 9 | P | Breast cancer | Phosphorylation | 36632451 |
S | 9 | P | Ovarian cancer/carcinoma | Phosphorylation | 23667667 |
S | 9 | P | Lung cancer/carcinoma | Phosphorylation | 23149922 |
S | 9 | P | Liver cancer | Phosphorylation | 23325562 |
S | 9 | P | Gastric cancer | Phosphorylation | 23123500 |
S | 9 | U | Lung adenocarcinoma | Phosphorylation | 33808696 |
S | 9 | U | Hepatocellular carcinoma | Phosphorylation | 34484860 |
S | 9 | U | Breast cancer | Phosphorylation | 17495324 ;  35173161 ;  17495324 |
S | 9 | U | Non-small cell lung cancer | Phosphorylation | 36869126 |
S | 9 | U | Lung cancer/carcinoma | Phosphorylation | 23514933 |
S | 9 | U | Melanoma | Phosphorylation | 35347072 |
S | 9 | U | Systemic scleroderma | Phosphorylation | 35853487 |
S | 9 | U | Systemic lupus erythematosus | Phosphorylation | 23735868 |
S | 9 | U | Squamous cell carcinoma | Phosphorylation | 18606491 |
S | 9 | U | Skin cancer | Phosphorylation | 18606491 |
S | 9 | U | Papillomas | Phosphorylation | 18606491 |
S | 9 | U | Ovarian cancer | Phosphorylation | 15208673 |
S | 9 | U | Neuroblastoma | Phosphorylation | 30154149 |
S | 9 | U | Major depressive disorder | Phosphorylation | 22622071 |
S | 9 | U | Lymphoma | Phosphorylation | 20224723 |
S | 9 | U | Granulomatosis with polyangiitis | Phosphorylation | 37720230 |
S | 9 | U | Dilated cardiomyopathy | Phosphorylation | 37852321 |
S | 9 | U | Diabetes mellitus | Phosphorylation | 35835217 |
S | 9 | U | Cardiomyopathy | Phosphorylation | 37852321 |
S | 9 | U | Breast cancer/tumor/carcinoma | Phosphorylation | 17495324 ;  27494834 |
S | 9 | U | Bipolar disorder | Phosphorylation | 16806104 |
S | 9 | U | Alzheimer's disease | Phosphorylation | 22278060 |
State Note: Based on the distinct PTM states in diseases, PTMD classified all disease-associated PTMs into six classes, including whether the up-regulation (U) or down-regulation (D) of PTM levels, the absence (A) or presence (P) of PTMs, and the creation (C) or disruption (N) of PTM sites are associated with diseases.
PTM-Drug Perturbation Response:
source: DecryptMProtein | Gene | PTM | Position | Modified sequence | Cell | Drug | pEC50 | Regulation | Experiment |
---|---|---|---|---|---|---|---|---|---|
P49841 | GSK3B | P | Ser9 | TTS(ph)FAESCKPVQQPSAFGSMK | HeLa | CUDC101 | 1 | up | |
P49841 | GSK3B | P | Ser9 | TTS(ph)FAESCKPVQQPSAFGSMK | A459 | MK2206 | 7.2049 | down | |
P49841 | GSK3B | P | Ser9 | TTS(ph)FAESCKPVQQPSAFGSMK | A459 | SelumetinibMK2206-1to2 | 7.4614 | down | |
P49841 | GSK3B | P | Ser9 | TTS(ph)FAESCKPVQQPSAFGSMK | A459 | SelumetinibMK2206-3to1 | 7.0611 | down | |
P49841 | GSK3B | P | Ser9 | TTS(ph)FAESCKPVQQPSAFGSMK | PC-9 | GeftinibAZD4547-1to80 | 8.6743 | down | |
P49841 | GSK3B | P | Ser9 | TTS(ph)FAESCKPVQQPSAFGSMK | PC-9 | Lapatinib | 6.6407 | down | |
P49841 | GSK3B | P | Ser9 | TTS(ph)FAESCKPVQQPSAFGSMK | A459 | MK2206 | 7.0039 | - | |
P49841 | GSK3B | P | Ser9 | TTS(ph)FAESCKPVQQPSAFGSMK | A459 | Selumetinib | 6.2144 | - | |
P49841 | GSK3B | P | Ser9 | TTS(ph)FAESCKPVQQPSAFGSMK | HeLa | Curcumin | 5.2589 | - | |
P49841 | GSK3B | P | Ser9 | TTS(ph)FAESCKPVQQPSAFGSMK | PC-9 | AZD4547 | 5.5148 | - | |
P49841 | GSK3B | P | Ser9 | TTS(ph)FAESCKPVQQPSAFGSMK | PC-9 | Gefitinib | 8.2709 | - |
pEC50 Note: pEC50 is the negative logarithm of EC50 (half-maximal effective concentration, dosage unit Mol), calculated as pEC50 = -log10(EC50), which quantifies the potency of a drug or compound.
Function score:
source: funscoRNo data.